Frédéric Antonio Carvalho Selected Research

Post-Infectious Disorders

1/2022

AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frédéric Antonio Carvalho Research Topics

Disease

3	Inflammation (Inflammations) 01/2022 - 01/2018
2	Infections 01/2022 - 01/2020
2	Hypersensitivity (Allergy) 01/2022 - 01/2019
1	Cognitive Dysfunction 01/2022
1	Post-Infectious Disorders 01/2022
1	Gastroenteritis 01/2022
1	Chronic Pain 01/2020
1	Visceral Pain 01/2019
1	Hyperalgesia 01/2019
1	Cystitis 01/2019
1	Pain (Aches) 01/2019
1	Interstitial Cystitis (Interstitial Cystitis, Chronic) 01/2019
1	Persistent Infection 01/2018
1	Cysts 01/2018
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 03/2007
1	Crohn Disease (Crohn's Disease) 03/2007

Drug/Important Bio-Agent (IBA)

2	Volatile Fatty AcidsIBA 01/2022 - 01/2020
2	CytokinesIBA 01/2022 - 01/2019
2	LigandsIBA 01/2020 - 01/2019
1	indoleIBA 01/2022
1	Interleukin-22 (IL-22)IBA 01/2022
1	Tryptophan (L-Tryptophan)FDA Link 01/2022
1	tryptopholIBA 01/2022
1	CalciumIBA 01/2019
1	Analgesics (Analgesic Drugs)IBA 01/2019
1	Prostaglandins BIBA 01/2019
1	Pregabalin (Lyrica)FDA Link 01/2019
1	NF-kappa B (NF-kB)IBA 01/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019
1	Purinergic P2X ReceptorsIBA 01/2018
1	AntibodiesIBA 03/2007

Therapy/Procedure

1	Therapeutics 01/2019
1	Intraperitoneal Injections 01/2019
1	Oral Administration 01/2018